AXSOME THERAPEUTICS, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances
AXSOME THERAPEUTICS, INC. (AXSM) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances of $2.15 million for the 12-month period ending 2017-12-31, per its 10-K filed 2019-03-15.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues · last filed 2019-03-15
- AXSOME THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for the quarter ending 2015-12-31 was $0.00.
- AXSOME THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for the quarter ending 2015-09-30 was $11.00K.
- AXSOME THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for the quarter ending 2015-06-30 was $836.10K.
- AXSOME THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for the quarter ending 2015-03-31 was $23.90K.
- AXSOME THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for fiscal 2017 was $2.15M.
- AXSOME THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for fiscal 2015 was $871.00K, a 14.98% increase from fiscal 2014.
- AXSOME THERAPEUTICS, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, issuances for fiscal 2014 was $757.53K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances 12 month |
|---|---|---|---|---|
| 2017-12-31 | $2.15M 10-K · filed 2019-03-15 | |||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $11.00K derived: sum of 2 quarters · filed 2018-03-07 | $847.10K derived: sum of 3 quarters · filed 2018-03-07 | $871.00K 10-K · filed 2018-03-07 |
| 2015-09-30 | $11.00K 10-Q · filed 2016-11-14 | $847.10K derived: sum of 2 quarters · filed 2016-11-14 | $871.00K 10-Q · filed 2016-11-14 | |
| 2015-06-30 | $836.10K 10-Q · filed 2016-08-09 | $860.00K 10-Q · filed 2016-08-09 | ||
| 2015-03-31 | $23.90K 10-Q/A · filed 2016-08-09 | |||
| 2014-12-31 | $757.53K 10-K · filed 2017-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |